Notably, treatment of normal and patient-derived CRC organoids with the ZNRF3*HER2 PROTAB led to tumour-specific degradation, whereas anti-HER2 bivalent antibody resulted in degradation in both normal cells and tumour cells (Extended Data Fig. 4b). This evidence concerns the gene ZNRF3 and neoplasm.